DE60330161D1 - Rifalazil zur behandlung von infektionen mit clostridium difficile - Google Patents
Rifalazil zur behandlung von infektionen mit clostridium difficileInfo
- Publication number
- DE60330161D1 DE60330161D1 DE60330161T DE60330161T DE60330161D1 DE 60330161 D1 DE60330161 D1 DE 60330161D1 DE 60330161 T DE60330161 T DE 60330161T DE 60330161 T DE60330161 T DE 60330161T DE 60330161 D1 DE60330161 D1 DE 60330161D1
- Authority
- DE
- Germany
- Prior art keywords
- rifalazil
- clostridium difficile
- infections
- treatment
- invention features
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D513/18—Bridged systems
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US40687302P | 2002-08-29 | 2002-08-29 | |
US44457003P | 2003-02-03 | 2003-02-03 | |
PCT/US2003/027305 WO2004019907A1 (en) | 2002-08-29 | 2003-08-29 | Methods and reagents for treating infections of clostridium difficile and diseases associated therewith |
Publications (1)
Publication Number | Publication Date |
---|---|
DE60330161D1 true DE60330161D1 (de) | 2009-12-31 |
Family
ID=31981443
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60330161T Expired - Lifetime DE60330161D1 (de) | 2002-08-29 | 2003-08-29 | Rifalazil zur behandlung von infektionen mit clostridium difficile |
Country Status (10)
Country | Link |
---|---|
US (1) | US20040106590A1 (de) |
EP (1) | EP1545453B1 (de) |
JP (1) | JP2006501310A (de) |
AT (1) | ATE448775T1 (de) |
AU (2) | AU2003268330A1 (de) |
CA (1) | CA2495144A1 (de) |
DE (1) | DE60330161D1 (de) |
ES (1) | ES2339003T3 (de) |
TW (1) | TW200500071A (de) |
WO (1) | WO2004019907A1 (de) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6969520B2 (en) * | 1997-10-20 | 2005-11-29 | Acambis Inc. | Active immunization against clostridium difficile disease |
US20040077533A1 (en) * | 2002-05-23 | 2004-04-22 | Sayada Chalom B. | Methods and compositions for treating bacterial infections and diseases associated therewith |
US20090149453A1 (en) * | 2002-05-23 | 2009-06-11 | Activbiotics Pharma Llc | Methods and compositions for treating bacterial infections and diseases associated therewith |
TW200418485A (en) * | 2002-09-23 | 2004-10-01 | Activbiotics Inc | Rifalazil compositions and therapeutic regimens |
JP2007503439A (ja) * | 2003-08-22 | 2007-02-22 | アクティブバイオティクス インコーポレイティッド | リファマイシンアナログおよびそれらの使用法 |
US7820652B2 (en) * | 2003-09-24 | 2010-10-26 | Activbiotics Pharma, Llc | Regimen for the administration of rifamycin-class antibiotics |
JP2007513961A (ja) * | 2003-12-10 | 2007-05-31 | アクティブバイオティクス インコーポレイティッド | リファマイシンアナログおよびその使用法 |
AU2004308399A1 (en) * | 2003-12-23 | 2005-07-14 | Activbiotics, Inc. | Rifamycin analogs and uses thereof |
CA2470090A1 (fr) * | 2004-06-18 | 2005-12-18 | Bio-K Plus International Inc. | Bacteries lactiques et leurs usages dans la prevention de diarrhee associee aux antibiotiques |
FR2882522B1 (fr) * | 2005-02-25 | 2007-04-13 | Aventis Pharma Sa | Composition pharmaceutique solide comprenant de la telithromycine |
CN100398546C (zh) * | 2005-06-29 | 2008-07-02 | 上海医药科技发展有限公司 | 碳青霉烯类抗生素法罗培南钠的制备方法 |
CN101340917A (zh) * | 2005-12-22 | 2009-01-07 | 惠氏公司 | 用替加环素治疗胃肠道感染的方法 |
CA2632213A1 (en) * | 2005-12-22 | 2007-07-05 | Wyeth | Oral formulations comprising tigecycline |
WO2007117556A2 (en) * | 2006-04-06 | 2007-10-18 | Activbiotics, Incorporated | Pharmaceutical compositions and uses thereof |
US8518873B2 (en) * | 2007-09-12 | 2013-08-27 | The Medicines Company | Method of inhibiting clostridium difficile by administration of oritavancin |
CN102143751A (zh) * | 2008-07-07 | 2011-08-03 | 活跃生物药物学有限公司 | 利福拉齐治疗结肠疾病的用途 |
MX2011003548A (es) | 2008-10-02 | 2011-06-21 | Salix Pharmaceuticals Ltd | Metodos para tratar la encefalopatia hepatica. |
US20110035232A1 (en) * | 2008-10-02 | 2011-02-10 | Salix Pharmaceuticals, Ltd. | Methods of treating hepatic encephalopathy |
US7928115B2 (en) * | 2008-10-02 | 2011-04-19 | Salix Pharmaceuticals, Ltd. | Methods of treating travelers diarrhea and hepatic encephalopathy |
DK2396652T3 (da) | 2009-02-11 | 2018-01-29 | Cedars Sinai Medical Center | Diagnose af inflammatorisk tarmsyndrom baseret på cytoletalt udspilende toksin |
MX2011008354A (es) * | 2009-02-11 | 2011-09-06 | Cedars Sinai Medical Center | Terapia antibiotica para reducir la probabilidad de desarrollar el sindrome del intestino irritable post-infeccioso. |
CA2778181A1 (en) | 2009-10-26 | 2011-05-05 | Thomas Julius Borody | Therapy for enteric infections |
WO2012138963A1 (en) * | 2011-04-06 | 2012-10-11 | The Board Of Regents Of The University Of Texas System | Inositol hexakisphosphate analogs and uses thereof |
MX2015003326A (es) | 2012-09-17 | 2015-08-12 | Cedars Sinai Medical Center | Diagnostico y tratamiento de trastornos de la motilidad de los intestinos y la vejiga, y de la fibromialgia. |
EP3160465A4 (de) * | 2014-06-24 | 2017-12-20 | The Board of Trustees of the Leland Stanford Junior University | Verwendung von kleinen molekülen zur behandlung von clostridium-difficile-toxizität |
WO2017120385A1 (en) * | 2016-01-06 | 2017-07-13 | California Institute Of Technology | Polymeric compositions and related systems and methods for regulating biological hydrogels |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1304363C (en) * | 1988-11-01 | 1992-06-30 | Takehiko Yamane | 3'-hydroxybenzoxazinorifamycin derivative, process for preparing the same and antibacterial agent containing the same |
US5007790A (en) * | 1989-04-11 | 1991-04-16 | Depomed Systems, Inc. | Sustained-release oral drug dosage form |
IL98087A (en) * | 1990-05-04 | 1996-11-14 | Perio Prod Ltd | Preparation for dispensing drugs in the colon |
US5266315A (en) * | 1990-05-07 | 1993-11-30 | Kabushiki Kaisha Miyarisan Seibutsu Igaku Kenkyusho | Composite for Clostridium difficile diarrhea and pseudomembranous colitis |
US5582837A (en) * | 1992-03-25 | 1996-12-10 | Depomed, Inc. | Alkyl-substituted cellulose-based sustained-release oral drug dosage forms |
JP3492688B2 (ja) * | 1992-10-09 | 2004-02-03 | 鐘淵化学工業株式会社 | 微細な造粒体の製造方法 |
ES2188657T3 (es) * | 1994-04-22 | 2003-07-01 | Yamanouchi Pharma Co Ltd | Sistema para la liberacion especifica en el colon de un farmaco. |
US5849327A (en) * | 1994-07-29 | 1998-12-15 | Advanced Polymer Systems, Inc. | Delivery of drugs to the lower gastrointestinal tract |
JPH10505358A (ja) * | 1994-09-06 | 1998-05-26 | ギャラゲン・インコーポレイテッド | クロストリジウム・ディフィシル関連疾患の治療処置 |
FI98343C (fi) * | 1995-03-21 | 1997-06-10 | Orion Yhtymae Oy | Peroraalinen formulaatio |
US5811388A (en) * | 1995-06-07 | 1998-09-22 | Cibus Pharmaceutical, Inc. | Delivery of drugs to the lower GI tract |
US5972389A (en) * | 1996-09-19 | 1999-10-26 | Depomed, Inc. | Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter |
ES2248908T7 (es) * | 1997-06-06 | 2014-11-24 | Depomed, Inc. | Formas de dosificación de fármacos por vía oral y retención gástrica para liberación continuada de fármacos altamente solubles |
KR100219918B1 (ko) * | 1997-07-03 | 1999-09-01 | 김윤 | 대장선택적 약물전달용 조성물 |
US6114310A (en) * | 1998-01-23 | 2000-09-05 | Microcide Pharmaceuticals, Inc. | Efflux pump inhibitors |
US5968554A (en) * | 1998-07-07 | 1999-10-19 | Cascade Development, Inc. A Subsidiary Of Cardinal Health, Inc. | Sustained release pharmaceutical preparation |
US6316433B1 (en) * | 1998-12-18 | 2001-11-13 | Kaneka Corporation | Method for treatment of bacterial infections with once or twice-weekly administered rifalazil |
US6270755B1 (en) * | 1999-05-13 | 2001-08-07 | Geltex Pharmaceuticals, Inc. | Anionic polymers as toxin binders |
US6696412B1 (en) * | 2000-01-20 | 2004-02-24 | Cubist Pharmaceuticals, Inc. | High purity lipopeptides, Lipopeptide micelles and processes for preparing same |
US6488962B1 (en) * | 2000-06-20 | 2002-12-03 | Depomed, Inc. | Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms |
AU2003239919A1 (en) * | 2002-06-03 | 2003-12-19 | Activbiotics, Inc. | Intravenous rifalazil formulation and methods of use thereof |
-
2003
- 2003-08-29 EP EP03749288A patent/EP1545453B1/de not_active Expired - Lifetime
- 2003-08-29 AU AU2003268330A patent/AU2003268330A1/en not_active Abandoned
- 2003-08-29 DE DE60330161T patent/DE60330161D1/de not_active Expired - Lifetime
- 2003-08-29 AT AT03749288T patent/ATE448775T1/de not_active IP Right Cessation
- 2003-08-29 TW TW092123881A patent/TW200500071A/zh unknown
- 2003-08-29 CA CA002495144A patent/CA2495144A1/en not_active Abandoned
- 2003-08-29 JP JP2004569768A patent/JP2006501310A/ja active Pending
- 2003-08-29 US US10/652,799 patent/US20040106590A1/en not_active Abandoned
- 2003-08-29 WO PCT/US2003/027305 patent/WO2004019907A1/en active Application Filing
- 2003-08-29 ES ES03749288T patent/ES2339003T3/es not_active Expired - Lifetime
-
2009
- 2009-10-12 AU AU2009225281A patent/AU2009225281A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
JP2006501310A (ja) | 2006-01-12 |
EP1545453B1 (de) | 2009-11-18 |
TW200500071A (en) | 2005-01-01 |
EP1545453A4 (de) | 2005-10-12 |
CA2495144A1 (en) | 2004-03-11 |
EP1545453A1 (de) | 2005-06-29 |
AU2003268330A1 (en) | 2004-03-19 |
ATE448775T1 (de) | 2009-12-15 |
US20040106590A1 (en) | 2004-06-03 |
ES2339003T3 (es) | 2010-05-14 |
AU2009225281A1 (en) | 2009-10-29 |
WO2004019907A1 (en) | 2004-03-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60330161D1 (de) | Rifalazil zur behandlung von infektionen mit clostridium difficile | |
ATE474592T1 (de) | Zusammensetzungen enthaltend lipase, protease und amylase zur behandlung von pankreasinsuffizienz | |
EA200601553A1 (ru) | Замещенные бензимидазол-, бензтриазол- и бензимидазолон-о-глюкозиды | |
ATE526991T1 (de) | Zusammensetzungen und ihre verwendungen für die gentherapeutische behandlung von knochenerkrankungen | |
EA200900802A1 (ru) | Способы и композиции для лечения амилоидных заболеваний | |
ATE453653T1 (de) | Platinkomplexe zur behandlung von tumoren | |
EA200600078A1 (ru) | Способы и композиции для лечения амилоидных заболеваний | |
DE602004031134D1 (de) | Pharmazeutische zusammensetzungen und verfahren zur verwendung von levodopa und carbidopa | |
DE60034871D1 (de) | Verfahren und zusammensetzungen zur prevention oder behandlung von krebs und von krebs assoziertem knochenverlust | |
ATE541848T1 (de) | Diaryl-purin, azapurine und deazapurine als nichtnukleoside reverse-transkriptase-inhibitoren zur behandlung von hiv | |
WO2003103581A3 (en) | COMPOSITIONS AND METHODS FOR LIVER GROWTH AND PROTECTION | |
ATE319439T1 (de) | Mittel zur behandlung von erkrankungen des tracheo-bronchialtraktes, insbesondere der copd | |
DE60326248D1 (de) | Verbindungen, zusammensetzungen und verfahren zur behandlung von zellulären proliferativen erkrankungen | |
ATE359816T1 (de) | Verfahren zur prävention und behandlung von infektionen mit dem flavivirus bei tieren | |
ATE302002T1 (de) | Verwendung von pyrazolderivaten zur behandlung von unfruchtbarkeit | |
DE602005021766D1 (de) | Verfahren zur behandlung von atherosklerose | |
DE602004028574D1 (de) | Zusammensetzungen und verfahren zur behandlung des reizdarmsyndroms und von nichtulzeröser dyspepsie | |
ATE410235T1 (de) | Behandlung von ballastwasser | |
ATE343398T1 (de) | Zusammensetzungen und verfahren zur behandlung von hyperimmunreaktionen im auge | |
ATE290857T1 (de) | Bretyliumhaltige zusammensetzungen und kits und deren verwendung zur vorbeugung und behandlung cardiovaskulärer erkrankungen | |
ATE406171T1 (de) | Aplidine zur behandlung von multiplem myelom | |
DE602004005821D1 (de) | Enteralpräparat zur vorbeugung gegen bzw. behandlung von sepsis | |
DE60142786D1 (de) | Zusammensetzungen und methoden zur behandlung von candidosen | |
ATE347888T1 (de) | Verwendung von aivlosin zur behandlung und prevention der lawsonia-infektionen in schweinen. | |
ATE350445T1 (de) | Zusammensetzung, ausrüstung und methode zur reinigung und/oder behandlung von oberflächen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition | ||
R082 | Change of representative |
Ref document number: 1545453 Country of ref document: EP Representative=s name: SCHUMACHER & WILLSAU PATENTANWALTSGESELLSCHAFT, DE |